Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive biomarkers for FOLFIRINOX response in pancreatic cancer
NL-OMON29299Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of folinic acid, fluorouracil, irinotecan and oxaliplatin in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Erasmus MC. Primary endpoint: Biomarker differences between responders and nonresponders. Started Feb 2018; status: active, not recruiting.
02
Drugs
folinic acidfluorouracilirinotecanoxaliplatin
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON29299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29299.